Westlake Dermatology And Cosmetic Surgery

CLIA Laboratory Citation Details

2
Total Citations
10
Total Deficiencyies
4
Unique D-Tags
CMS Certification Number 45D2246068
Address 8825 Bee Caves Road Lower Level Suite B, Austin, TX, 78746
City Austin
State TX
Zip Code78746
Phone(512) 328-3376

Citation History (2 surveys)

Survey - July 16, 2024

Survey Type: Standard

Survey Event ID: YHK111

Deficiency Tags: D0000 D5391 D6107 D0000 D5391 D6107

Summary:

Summary Statement of Deficiencies D0000 The laboratory was surveyed and found to be in compliance with the Conditions of the CLIA regulations found at 42 CFR 493.1 through 493.1780, and recertification is recommended. Standard level deficiencies were cited. D5391 PREANALYTIC SYSTEMS QUALITY ASSESSMENT CFR(s): 493.1249(a) The laboratory must establish and follow written policies and procedures for an ongoing mechanism to monitor, assess, and when indicated, correct problems identified in the preanalytic systems specified at 493.1241 through 493.1242. This STANDARD is not met as evidenced by: Based on review of the laboratory's policy and procedure, test reports, and interview the laboratory failed to identify that the removal of the date on the slides made it impossible to determine when the quality control was prepared for one of 10 cases reviewed. Findings follow. A. Review of the laboratory policy and procedure titled Quality Assessment Plan under Purpose stated, "a quality assessment plan [was] designed to monitor and evaluate the ongoing and overall quality of pre-analytical, analytical, and post-analytical testing as a total process. The process begins with the test order and continues through collection, handling, testing of samples, and transmitting a report back to the person authorized to receive the results." B. Review of patient reports showed for case number PDP23-00123 was received on 07/21/2023 and reported on 07/24/2023. Review of the quality control slides for PAS showed quality control slides for the following dates: 07/21/2023 and 07/25/2023. Without dates on the slides, it was difficult to determine what date the patient/control slides were made. C. Interview with the Laboratory Manager on July 16, 2024 at 1725 hours acknowledged it was laboratory practice that on Day 1 the slide was processed, Day 2 the slides were interpreted and additional stains requested if needed, Day 3 additional slides prepared, and Day 4 slides interpreted. He confirmed it was impossible to Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- determine when the slides were prepared without the date on the slide and acknowledged the slide may have been misfiled. And on July 16, 2024 at 1800 hours acknowledged they used to put the date prepared on the slides, but stopped including the date around July 2023 (elapsed time one year). D. Review of pre-survey paperwork showed the estimated annual test volume for dermatopathology was 36090. D6107 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(15) The laboratory director must specify, in writing, the responsibilities and duties of each consultant and each supervisor, as well as each person engaged in the performance of the preanalytic, analytic, and postanalytic phases of testing, that identifies which examinations and procedures each individual is authorized to perform, whether supervision is required for specimen processing, test performance or result reporting and whether supervisory or director review is required prior to reporting patient test results. This STANDARD is not met as evidenced by: Based on review of test reports, laboratory records and interview, the laboratory director failed to specify in writing the responsibilities and duties for two of three technical supervisors performing diagnostic interpretations in dermatopathology. Findings follow. A. Review of dermatopathology test reports (DP24-13254, DP24- 13448, DP23-19730) showed three personnel performing diagnostic interpretations: technical supervisor position required, per 42 CFR 493.1273 (b). B. Review of laboratory records found no written delegation of responsibilities and duties for technical supervisors #2 and 3 (as listed on the CMS form 209). C. Interview with the Laboratory Manager on July 16, 2024 at 1030 hours confirmed they currently had three dermatopathologists that performed diagnostic interpretations and written delegation of duties were not available for technical supervisors #2 and 3. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - October 12, 2022

Survey Type: Standard

Survey Event ID: MS9E11

Deficiency Tags: D0000 D3011 D0000 D3011

Summary:

Summary Statement of Deficiencies D0000 Noted deficiencies and plans of correction were discussed with the laboratory representatives at the exit conference. The facility was found to be in compliance with applicable Conditions of Participation in the CLIA program, and certification is recommended. D3011 FACILITIES CFR(s): 493.1101(d) Safety procedures must be established, accessible, and observed to ensure protection from physical, chemical, biochemical, and electrical hazards, and biohazardous materials. This STANDARD is not met as evidenced by: Based on review of the laboratory's policies and procedures, formaldehyde badge test, and interview, the laboratory failed to repeat the formaldehyde exposure monitoring test after a failed test occurred for one of two random employees tested in the last year. Findings follow. A. Review of the laboratory's policy and procedure titled Westlake Dermatopathology and Cosmetic Surgery Chemical Hygiene Plan, approved 10/10/2022, stated under "XII. Xylene and Formaldehyde Monitoring: ... 2. Formaldehyde is a common chemical used as a tissue preservative in laboratories. Formaldehyde is a common sensitizing agent found in laboratories that can trigger an allergic reaction in normal tissue after single or repeated exposures. It is also classified as a known to be a human carcinogen. Small formaldehyde specimen containers are used in the clinic. Samples are sent to a reference lab for processing. Monitoring is not required." The procedure does not recognize the laboratory is a grossing laboratory and does cut and stain specimens preserved in formaldehyde. B. Review of the Formaldehyde Personal Monitoring Badge test performed on December 21, 2021, showed a badge test failed for testing personnel #3, as listed on the CMS form 209. The Monitoring Compliance Information stated, for "OSHA: 0.75 ppm 8- Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- hour TWA; 2.0 ppm 15-minute STEL; 0.5 ppm 8-hour Action Level". And at requirements stated, "If the last monitoring results reveal employee exposure at or above the action level, the employer shall repeat the monitoring of the employees." The results for Badge SFM21714 reported on January 6, 2022, was 8-hour TWA: 0.54 ppm. C. Interview with the grossing lab manager on October 12, 2022, at 1325 in the conference room acknowledged that he missed that and will repeat it. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access